Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$10.35 - $17.11 $3,757 - $6,210
363 Added 30.3%
1,561 $25,000
Q2 2023

Aug 10, 2023

BUY
$12.93 - $18.76 $3,710 - $5,384
287 Added 31.5%
1,198 $20,000
Q3 2022

Nov 14, 2022

BUY
$10.5 - $22.01 $9,565 - $20,051
911 New
911 $16,000

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $65.5M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.